^
Association details:
Biomarker:PTTG1 overexpression
Cancer:Renal Cell Carcinoma
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response

Published date:
01/17/2022
Excerpt:
As depicted in Figure 8(F), PTTG1 expression was significantly associated with overall survival in multivariate regression in the FUSCC cohort….The retrospective analysis (Figure 8(G,H)) indicated that elevated PTTG1 expression was significantly associated with better ICB response (χ2=3.99, p < .05) and PTTG1 may serve as a stable biomarker for immunotherapy (AUC = 0.679, p = .009)....As a higher PTTG1 expression level was significantly associated with ICB response, high PTTG1 expression may be also associated with a better prognosis among pRCC patients receiving ICB.
DOI:
https://doi.org/10.1080/07853890.2021.2011956